

COMPANY UPDATE

Centurion Corp (CENT SP)

Continuing On Its Recovery Across All Asset Classes

Centurion's 1Q23 business update was a solid one with revenue up 5% yoy to S\$47m making up 25% of our full-year forecast and thus in line with expectation. The key PBWA segment, which makes up three-quarters of its revenue, saw 5% yoy growth in its top-line while its PBSA segment was similarly robust, up 7% yoy. In the near to medium term, it appears that Centurion will continue to see incremental volume and rental growth. Maintain BUY. Target price: S\$0.43.

1Q23 BUSINESS UPDATE

Year to 31 Dec (S\$ '000)	1Q22	1Q23	yoy chg	Remarks
Total revenue	45,054	47,142	+4.6%	
By business segment				
Workers accommodation	33,445	35,237	+5.4%	Continuing strength in Singapore and Malaysia
Student accommodation	10,972	11,725	+6.9%	
Others	637	180	-71.7%	Due to sale of dwell Dongdaemun, South Korea
By geographical area				
Singapore	30,642	30,472	-0.6%	
Malaysia	3,440	4,945	+43.8%	Material improvement in occupancy rate for PBWA
United Kingdom	1,823	3,156	+73.1%	Strong domestic & international demand for PBSA
Australia	8,558	8,137	-4.9%	
Others	591	432	-26.9%	

Source: Centurion, UOB Kay Hian

WHAT'S NEW

- Slowly but surely grinding higher.** Centurion Corp (Centurion) reported a positive 1Q23 business update with its key purpose built workers' accommodation (PBWA, 75% of revenue) segment witnessing a 5% yoy revenue increase due to: a) 2ppt yoy increase in occupancy rate to 98% in Singapore, and b) a significant increase in occupancy rate in Malaysia, up from 68% in 1Q22 to 93% in 1Q23. In addition, the company stated that rental reversions were healthy and with its ability to pass on inflation and higher costs, it would appear that profit margins have easily been maintained, in our view.
- Student accommodation taking slightly longer to recover after COVID-19.** As opposed to its PBWA assets, the company's purpose built student accommodation (PBSA) segment has taken slightly longer to recover its occupancy rates given the seasonality of student entries into UK and Australian universities. As a result, occupancy at UK and Australian PBSA assets were 90% and 80% respectively, although it should be noted that both geographic segments have witnessed robust pre-bookings for the forward academic years, and rental reversions have tracked at 8-10% yoy increase.

KEY FINANCIALS

Year to 31 Dec (S\$m)	2021	2022	2023F	2024F	2025F
Net turnover	143	180	187	192	195
EBITDA	79	118	113	118	121
Operating profit	76	115	102	105	107
Net profit (rep./act.)	53	71	60	68	69
Net profit (adj.)	53	71	60	68	69
EPS (S\$ cent)	6.3	8.5	7.1	8.1	8.3
PE (x)	5.4	4.0	4.8	4.2	4.1
P/B (x)	0.4	0.4	0.4	0.4	0.4
EV/EBITDA (x)	11.0	7.4	7.7	7.4	7.2
Dividend yield (%)	1.5	1.5	4.2	4.8	4.9
Net margin (%)	36.8	39.6	32.1	35.3	35.5
Net debt/(cash) to equity (%)	100.1	86.6	76.0	78.5	74.5
Interest cover (x)	3.5	4.2	3.4	4.5	4.7
ROE (%)	8.3	10.6	8.4	9.3	9.7
Consensus net profit	-	-	60	65	67
UOBKH/Consensus (x)	-	-	1.00	1.04	1.04

Source: Centurion, Bloomberg, UOB Kay Hian

BUY

(Maintained)

Share Price	S\$0.34
Target Price	S\$0.43
Upside	+26.5%


COMPANY DESCRIPTION

Centurion is one of the largest providers of purpose-built workers' accommodations in Singapore and Malaysia, and has exposure to student accommodation in UK and Australia.

STOCK DATA

GICS sector	Real Estate			
Bloomberg ticker:	CENT SP			
Shares issued (m):	840.8			
Market cap (S\$m):	285.9			
Market cap (US\$m):	212.5			
3-mth avg daily t'over (US\$m):	0.0			
Price Performance (%)				
52-week high/low	S\$0.420/S\$0.325			
1mth	3mth	6mth	1yr	YTD
(6.8)	(5.6)	4.6	(4.2)	1.5
Major Shareholders		%		
Centurion Properties P/L		50.6		
Teo Peng Kwang		7.6		
Han Seng Juan		5.3		
FY23 NAV/Share (S\$)		0.87		
FY23 Net Debt/Share (S\$)		0.66		

PRICE CHART



Source: Bloomberg

ANALYST(S)

Adrian Loh
 +65 6590 6633
 adrianloh@uobkayhian.com

STOCK IMPACT

- Volume growth underpins earnings in the next three years.** We highlight that Centurion has volume growth in Singapore in 2023 with the Jurong Town Council allowing for higher bed count at its Quick Build Dormitories while Malaysia will see an increase of 290 beds at Tampoi, plus the new Westlite Cemerlang asset coming onstream in 3Q23 with 1,650 beds. In addition, the company could also look to add new PBWA assets in Malaysia in the near to medium term given the dearth of quality supply in the country.
- Looking forward to higher dividend payout.** We note that Centurion does not have a fixed dividend policy at present, however during pre-COVID-19 years it paid out >38% of its net profits. In our view, management's stance in wanting to conserve its cash resources may be overly conservative and it could instead enunciate a payout ratio which would attract more investor interest. We have used a payout ratio of 20% for 2023-25.
- Sale of Korean asset and exiting the market.** In Apr 23, Centurion announced that it had sold its dwell Dongdaemun asset in South Korea to Ganghwa County of Incheon Metropolitan City for KRW21.25b (S\$21.4m). The company did not see any growth potential for PBSA assets in Korea and thus elected to exit the market and will look to instead redeploy its capital to other geographies with PBWA assets in Malaysia a likely target. The sale price for dwell Dongdaemun equated to 1x P/B based on Centurion's audited financial statements as at 31 Dec 22, and was a healthy increase vs its purchase price of KRW13b in 3Q18.
- Solid balance sheet.** As at end-1Q23, Centurion had total borrowings of S\$0.7b, cash and undrawn committed facilities totalling S\$222m, and 44% net gearing (net debt/net debt + equity). With an interest cover ratio of 3.4x and average debt maturity of around six years, we do not foresee any financial stress on Centurion.

EARNINGS REVISION/RISK

- Upgrades to earnings.** Changes to our earnings forecasts for 2023-25 incorporate: a) the sale of dwell Dongdaemun, b) higher occupancy rates for PBWA assets in Singapore and Malaysia, and c) new contribution from Westlite Cemerlang from 3Q23 onwards. We highlight that there could be earnings upside from the extension of leases at Centurion's Quick Build Dormitories in Singapore which we have not accounted for yet.

VALUATION/RECOMMENDATION

- Maintain BUY with an unchanged PE and P/B based target price of S\$0.43.** Our PE target multiple of 5.8x is 1SD above Centurion's past five-year average of 4.8x (excluding 2020 which was impacted by COVID-19) and results in a valuation of S\$0.42 while our P/B target multiple of 0.5x (in line with its past five-year average P/B) is S\$0.44. We like the company for its ability to pass on higher costs to its customers in both its PBWA and PBSA business segments, and with Singapore and Malaysia's structural undersupply of workers' accommodation unlikely to abate in the near to medium term, the likelihood of positive rental reversions is high in our view.

SHARE PRICE CATALYST


- Capacity expansions involving JVs which are more asset light and require less capital intensity.
- Evidence that overseas Chinese students have resumed international studies.
- Establishment of a dividend policy and better capital management.

FIVE YEAR P/B CHART




Source: Bloomberg, UOB Kay Hian

REVENUE GROWTH: 1Q23 VS 1Q22 (S\$ '000)



Source: Centurion

TREND IN HALF-YEARLY REVENUE AND GROSS PROFIT



Source: Centurion

CHANGES TO EARNINGS FORECASTS

S\$m	2023F	2024F	2025F
NPAT - was	58.9	66.7	68.1
NPAT - is	60.0	68.0	69.4
Change	1.8%	1.9%	1.8%

Source: UOB Kay Hian

PROFIT & LOSS

Year to 31 Dec (\$m)	2022	2023F	2024F	2025F
Net turnover	180.5	186.9	192.4	195.5
EBITDA	118.4	112.8	117.5	121.0
Deprec. & amort.	3.7	10.8	12.5	14.3
EBIT	114.7	102.0	105.0	106.7
Associate contributions	8.9	8.3	8.5	8.6
Net interest income/(expense)	(28.3)	(33.3)	(25.9)	(25.9)
Pre-tax profit	95.3	77.1	87.6	89.4
Tax	(19.0)	(13.1)	(15.0)	(15.4)
Minorities	(4.9)	(4.1)	(4.6)	(4.7)
Preferred dividends	0.0	0.0	0.0	0.0
Net profit	71.4	60.0	68.0	69.4
Net profit (adj.)	71.4	60.0	68.0	69.4

BALANCE SHEET

Year to 31 Dec (\$m)	2022	2023F	2024F	2025F
Fixed assets	7.5	0.0	0.0	0.0
Other LT assets	1,448.5	1,450.7	1,437.3	1,437.3
Cash/ST investment	68.3	180.2	173.1	212.2
Other current assets	23.5	23.5	23.1	23.1
Total assets	1,547.8	1,654.3	1,633.5	1,672.7
ST debt	80.0	55.8	55.8	55.8
Other current liabilities	85.6	87.6	30.5	30.5
LT debt	583.1	683.3	683.3	683.3
Other LT liabilities	90.6	67.2	117.1	170.1
Shareholders' equity	686.9	734.9	721.3	707.4
Minority interest	21.6	25.6	25.6	25.6
Total liabilities & equity	1,547.8	1,654.3	1,633.5	1,672.7

CASH FLOW

Year to 31 Dec (\$m)	2022	2023F	2024F	2025F
Operating	103.0	101.3	59.1	105.6
Pre-tax profit	76.3	64.1	72.6	74.1
Tax	(7.2)	(13.1)	(15.0)	(15.4)
Deprec. & amort.	3.7	10.8	12.5	14.3
Associates	(8.9)	(8.3)	(8.5)	(8.6)
Working capital changes	12.0	1.5	(43.4)	0.0
Non-cash items	27.2	46.3	40.9	41.2
Other operating cashflows	0.0	0.0	0.0	0.0
Investing	(1.7)	(18.3)	(25.0)	(25.0)
Capex (growth)	(1.3)	(25.0)	(25.0)	(25.0)
Capex (maintenance)	(4.5)	0.0	0.0	0.0
Investments	3.6	6.7	0.0	0.0
Proceeds from sale of assets	0.6	0.0	0.0	0.0
Others	0.0	0.0	0.0	0.0
Financing	(100.2)	30.7	(39.5)	(39.7)
Dividend payments	(9.4)	(12.0)	(13.6)	(13.9)
Issue of shares	0.0	0.0	0.0	0.0
Proceeds from borrowings	63.7	75.9	0.0	0.0
Loan repayment	(125.5)	0.0	0.0	0.0
Others/interest paid	(29.0)	(33.3)	(25.9)	(25.9)
Net cash inflow (outflow)	1.1	113.6	(5.4)	40.9
Beginning cash & cash equivalent	67.5	66.6	178.4	171.4
Changes due to forex impact	(0.3)	0.0	0.0	0.0
Ending cash & cash equivalent	68.3	180.2	173.1	212.2

KEY METRICS

Year to 31 Dec (%)	2022	2023F	2024F	2025F
Profitability				
EBITDA margin	65.6	60.4	61.1	61.9
Pre-tax margin	52.8	41.3	45.5	45.8
Net margin	39.6	32.1	35.3	35.5
ROA	4.6	3.7	4.1	4.2
ROE	10.6	8.4	9.3	9.7
Growth				
Turnover	26.2	3.6	2.9	1.6
EBITDA	49.6	(4.7)	4.2	2.9
Pre-tax profit	40.3	(19.0)	13.6	2.1
Net profit	35.6	(16.0)	13.3	2.1
Net profit (adj.)	35.6	(16.0)	13.3	2.1
EPS	35.6	(16.0)	13.3	2.1
Leverage				
Debt to total capital	48.3	49.3	49.7	50.2
Debt to equity	96.5	100.6	102.5	104.5
Net debt/(cash) to equity	86.6	76.0	78.5	74.5
Interest cover (x)	4.2	3.4	4.5	4.7

Disclosures/Disclaimers

This report is prepared by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor an advice or a recommendation with respect to such securities.

This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of the recommendation, before the person makes a commitment to purchase the investment product.

This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of this report to any other person without the prior written consent of UOBKH. This report is not directed to or intended for distribution to or use by any person or any entity who is a citizen or resident of or located in any locality, state, country or any other jurisdiction as UOBKH may determine in its absolute discretion, where the distribution, publication, availability or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (as defined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.

The information or views in the report ("Information") has been obtained or derived from sources believed by UOBKH to be reliable. However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH accepts no liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected persons may have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and its connected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time, including before its publication herein.

Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to the extent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicit business from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit business from, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers, employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s) referred to in this report. (All of the foregoing is hereafter referred to as the "Subject Business"); and (4) UOBKH may otherwise have an interest (including a proprietary interest) in the subject corporation(s) referred to in this report.

As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest in the securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.

IMPORTANT DISCLOSURES FOR U.S. PERSONS

This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore. UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directly or through its US registered broker dealer affiliate named below) to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"). All US persons that receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities.

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc ("UOBKHUS"), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through UOBKH.

UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Analyst Certification/Regulation AC

Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report accurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was produced independently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of the Subject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and will not receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, the compensation received by each such research analyst is based upon various factors, including UOBKH's total revenues, a portion of which are generated from UOBKH's business of dealing in securities.

Reports are distributed in the respective countries by the respective entities and are subject to the additional restrictions listed in the following table.

General	This report is not intended for distribution, publication to or use by any person or entity who is a citizen or resident of or located in any country or jurisdiction where the distribution, publication or use of this report would be contrary to applicable law or regulation.
Hong Kong	This report is distributed in Hong Kong by UOB Kay Hian (Hong Kong) Limited ("UOBKHHK"), which is regulated by the Securities and Futures Commission of Hong Kong. Neither the analyst(s) preparing this report nor his associate, has trading and financial interest and relevant relationship specified under Para. 16.4 of Code of Conduct in the listed corporation covered in this report. UOBKHHK does not have financial interests and business relationship specified under Para. 16.5 of Code of Conduct with the listed corporation covered in this report. Where the report is distributed in Hong Kong and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKHHK (and not the relevant foreign research house) in Hong Kong in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Hong Kong who is not a professional investor, or institutional investor, UOBKHHK accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Indonesia	This report is distributed in Indonesia by PT UOB Kay Hian Sekuritas, which is regulated by Financial Services Authority of Indonesia ("OJK"). Where the report is distributed in Indonesia and contains research analyses or reports from a foreign research house, please note recipients of the analyses or reports are to contact PT UOBKH (and not the relevant foreign research house) in Indonesia in respect of any matters arising from, or in connection with, the analysis or report.
Malaysia	Where the report is distributed in Malaysia and contains research analyses or reports from a foreign research house, the recipients of the analyses or reports are to contact UOBKHM (and not the relevant foreign research house) in Malaysia, at +603-21471988, in respect of any matters arising from, or in connection with, the analysis or report as UOBKHM is the registered person under CMSA to distribute any research analyses in Malaysia.
Singapore	This report is distributed in Singapore by UOB Kay Hian Private Limited ("UOBKH"), which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note: (i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of any matters arising from, or in connection with, the analysis or report; and (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports only to the extent required by law.
Thailand	This report is distributed in Thailand by UOB Kay Hian Securities (Thailand) Public Company Limited, which is regulated by the Securities and Exchange Commission of Thailand.
United Kingdom	This report is being distributed in the UK by UOB Kay Hian (U.K.) Limited, which is an authorised person in the meaning of the Financial Services and Markets Act and is regulated by The Financial Conduct Authority. Research distributed in the UK is intended only for institutional clients.
United States of America ('U.S.')	This report cannot be distributed into the U.S. or to any U.S. person or entity except in compliance with applicable U.S. laws and regulations. It is being distributed in the U.S. by UOB Kay Hian (US) Inc, which accepts responsibility for its contents. Any U.S. person or entity receiving this report and wishing to effect transactions in any securities referred to in the report should contact UOB Kay Hian (US) Inc. directly.

Copyright 2023, UOB Kay Hian Pte Ltd. All rights reserved.

<http://research.uobkayhian.com>

RCB Regn. No. 197000447W